Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 2.7% ...

Haemonetics Corporation (NYSE:HAE) reported fiscal third-quarter 2026 results on Thursday that exceeded analyst expectations, ...

Haemonetics (HAE) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.19 per share a year ago. These figures ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices. Boston-based Haemonetics, which is ...

In the latest quarter, 5 analysts provided ratings for Haemonetics (NYSE:HAE), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

Haemonetics (NYSE:HAE) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of ...

Haemonetics Corporation (NYSE: HAE) on Friday said it will acquire Ireland-based Vivasure Medical Limited, a move aimed at strengthening its position in structural heart and endovascular procedures, ...

AlphaQuest LLC boosted its position in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 36,520.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...